Clinical trials
Lymphoma, T-Cell, Peripheral trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
17 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 11 |
| Active, not recruiting | 3 |
| Recruiting | 2 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fred Hutchinson Cancer Center | 3 |
| SecuraBio | 2 |
| The Lymphoma Academic Research Organisation | 2 |
| Aarhus University Hospital | 1 |
| Acrotech Biopharma Inc. | 1 |
| Affimed GmbH | 1 |
| AstraZeneca | 1 |
| Celgene | 1 |
| Daiichi Sankyo | 1 |
| Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoma, T-Cell, Peripheral | 17 |
| Lymphoma, Non-Hodgkin | 6 |
| Recurrence | 6 |
| Immunoblastic Lymphadenopathy | 4 |
| Lymphoma | 4 |
| Lymphoma, Large B-Cell, Diffuse | 4 |
| Lymphoma, T-Cell | 4 |
| Lymphoma, T-Cell, Cutaneous | 4 |
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 4 |
| Burkitt Lymphoma | 3 |
Trials
Showing 26 to 17 of 17. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.